Article Text

SAT0341 Immune Response to Hepatitis B Virus Vaccination in Patients with Spondyloarthritis Treated with Anti-TNF Therapy VS Hemodialyzed Patients
  1. E. Valls Pascual1,
  2. M. Fernández Matilla2,
  3. I. De La Morena Barrio1,
  4. D. Ybáñez García1,
  5. P. Molina Vila3,
  6. C. Feced Olmos4,
  7. M. Robustillo Villarino1,
  8. F. Gil Latorre1,
  9. M.J. Buch García5,
  10. D. Bautista Rentero5,
  11. À. Martínez Ferrer1,
  12. J.E. Oller Rodríguez1,
  13. E. Vicens Bernabeu1,
  14. C. Vergara Dangond1,
  15. J.J. Alegre Sancho1
  1. 1Rheumatology, Hospital Universitari Doctor Peset
  2. 2Rheumatology, Hospital Arnau de Vilanova
  3. 3Nephrology, Hospital Universitari Doctor Peset
  4. 4Rheumatology, Hospital Universitari i Politècnic La Fe
  5. 5Medicina Preventiva, Hospital Universitari Doctor Peset, Valencia, Spain


Background Hepatitis B virus (HBV) vaccination is recommended in patients with inflammatory arthropaties on biologic treatment. Usually these patients cannot complete the vaccination schedule before starting biologic therapy.

Lower immune response to HBV vaccination was observed in rheumatoid arthritis patients treated with non-biologic DMARDs compared with general populationin a study published in 2002. The effect of anti-TNF therapy (antiTNF) on humoral response to influenza vaccination in patients with inflammatory arthropaties has been assessed afterwards. In a study published in 2010 a lower response was observed in patients with spondyloarthropaties (SpA) compared to a healthy sample.

Up to the present moment the inmunne response to HBV vaccination in patients with SpA treated with antiTNF has not yet been assessed.

Objectives Main objective: to evaluate the effect of antiTNF therapy on immune response to HBV vaccination in SpA patients.

Secondary objetives: to identify potential effect modifiers on immune response to HBV vaccination; comparison with a group of hemodialyzed patients (HD).

Methods Study type: This is an observational cohort study both prospective and retrospective. Patients and procedures: SpA group: Patients with SpA treated with antiTNF. They recieved 3 doses of HBV vaccination. HD group: Patients on HD who had recieved HBV vaccination following HD schedule.

Stadistic analysis Proportions for categorical variables and average ± SD (or median if appropiate) for continuous variables were calculated. Categorical variables were compared by chi-square test (applying continuity correction if necessary). T-test (or Kruskal-Wallis if appropiate) was used to compare averages.

Results 30 patients in the SpA group and 19 patients in the HD group were included. 17 patients (89.5%) in the HD group showed immune response to HBV vaccination whereas only 14 patients (46.7%) in the SpA group did. Immune response to vaccination was independent of any of the variables analyzed in the SpA group. When immune response was compared between the two different doses of vaccination (including all patients both from the SpA and the HD groups), a significant statistical difference was observed (p=0.034). The proportion of 'responders' was higher if the dose recieved was 40 mcg/mL.

Conclusions In our study, immune response to HBV vaccination in patients with SpA treated with antiTNF was lower than in hemodialyzed patients and general population. The proportion of response was larger in patients who recieved the higher dose of vaccination.This study is limited by the small sample size. It wood be useful to continue our investigation in order to ameliorate the vaccination standards of our patients.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3302

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.